Healthcare Industry News:  Vascular Stent 

Devices Interventional Cardiology Personnel

 News Release - March 4, 2008

MIV Therapeutics Announces Changes to Its Scientific Advisory Board

ATLANTA, GA--(Healthcare Sales & Marketing Network)--Mar 4, 2008 -- MIV Therapeutics, Inc. (OTC BB:MIVT.OB ) (Frankfurt:MIV.F ), a leading developer of next-generation coatings and advanced drug delivery systems for cardioVascular Stents and other implantable medical devices, today announced changes to its Scientific Advisory Board and Clinical Advisory Group.

Jeffrey W. Moses, M.D., Professor and Director of the Center for Interventional Vascular Therapy (CIVT) at Columbia University Medical Center (CUMC), Director of the Cardiac Catheterization Lab at New York-Presbyterian Hospital/CUMC and key faculty member of the Cardiovascular Research Foundation (CRF), has joined as Chair of the Company's Scientific Advisory Board. He joins Drs. David Cohen, Spencer King, Greg Kaluza, and Joseph Carrozza, who have been associated with the company since 2006.

In addition, Martin B. Leon, M.D., Professor of Medicine and Associate Director of the CIVT at CUMC, a practicing interventional cardiologist at New York-Presbyterian Hospital/CUMC and Chairman Emeritus of the CRF, joins the Company's Clinical Advisory Group, alongside Drs. Raoul Bonan and Alexandre Abizaid, who have been associated with the company since 2006 and 2007 respectively.

"We are proud to welcome Drs. Moses and Leon as solid additions to our Scientific Advisory Board and Clinical Advisory Group, respectively; I believe they are ideally suited to serve in this important role," said Dr. Mark Landy, president and chief executive officer of MIV. "They will provide valuable insight and help guide our research and development programs as the Company's proprietary technologies progress from the laboratory to the marketplace -- an area that is more important than ever to MIV's business and long-term success." Landy continued, "I am confident that MIV will benefit from Drs. Moses and Leon's unique and deep understanding in the fields of Interventional Cardiology and Drug Eluting Stents, and the many opportunities that lie ahead."

Drs. Wilbert Keon and Arun Chockalingam are stepping down from the Scientific Advisory Board, to allow for additional new members, who are experts in the field of Interventional Cardiology. "We are immensely grateful for their efforts and on behalf of the board, I want to thank them for their many contributions to MIV over the years -- and for helping to lay a firm foundation for future success," Dr. Landy added.

The role of the Scientific Advisory Board is to review and advise the Company's management and Board of Directors on scientific strategies and procedures and to provide input and critique on the Company's research and development activities. The Clinical Advisory Group is a proactive group that assists management in making clinically relevant day-to-day decisions.

About MIV Therapeutics

MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardioVascular Stents, as well as for a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. This coating platform is derived from hydroxyapatite (HAp), an organic material that has demonstrated excellent in vivo safety and biocompatibility. Hydroxyapatite is a porous material that makes up the bone mineral and matrix of teeth, and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug-eluting technologies based on HAp could also provide an attractive alternative to current polymer-based drug-eluting coatings on the stent market, which have been associated with undesirable effects. The Company's drug-eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIV Therapeutics has a Collaborative Research Agreement with the University of British Columbia and has received a government grant for its research program on the "Development of Novel Drug Eluting Composite Coatings for CardioVascular Stents," under the National Research Council-Industrial Research Assistance Program. Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization. MIV's intellectual property portfolio includes patents held by the University of British Columbia and exclusively licensed to MIV. Key patent applications filed simultaneously in various countries around the world further protect the commercial exclusivity of MIV's inventions in the global marketplace. For more information, please visit

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "proposed," "expected," "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties including, without limitation, the closing of the Share Purchase Agreement, the ability of the Company to raise sufficient funding and to continue to develop its various business interests as presently contemplated. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Source: MIV Therapeutics

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.